Articles tagged with Immunotherapy
A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...
A study investigating combination checkpoint immunotherapy in lethal advanced prostate cancer revealed that genetic subsets of patients with AR-V7+ prostate cancer may benefit from treatment. One-quarter of patients achieved an objective response, and at least two remain alive for over 18 months.
UCSF researchers identified a critical immune cell pathway that primes the immune system for effective response to checkpoint inhibitors. The presence of specific immune cells, such as dendritic cells and natural killer cells, in tumors predicts improved response to immunotherapy and overall survival. These findings enable clinicians t...
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A new study found that a pattern of genetic changes in prostate tumours can predict which men are likely to benefit from immunotherapy. The research identified a distinct group of men with advanced prostate cancer whose tumours have biological features that make them responsive to immunotherapy drugs.
A new method for predicting treatment success in cancer patients using immunotherapy has been discovered. This method relies on a protein called PD-1, which is found on the surface of human immune cells and allows them to detect tumors more effectively.
A novel immunotherapy treatment combining a molecule expressed by cancer cells with Listeria monocytogenes has shown promising results in clinical trials for dogs with osteosarcoma. The vaccine supplements standard treatment and has been shown to improve survival times, with median survival of 956 days compared to 423 days.
Researchers found that using nanoparticles to bind molecules can trigger immune cells more effectively against cancer in laboratory studies. The combination of two therapeutics on a single nanoparticle showed higher rates of T-cell stimulation and tumor attack than separate deliveries.
A Melbourne research team discovered that a protein called NF-kB1, which was previously thought to drive cancer development, actually plays a critical role in preventing stomach cancers. The study also found that immunotherapy may be a significant tool for treating stomach cancers driven by chronic inflammation.
The US FDA approved the combination of ipilimumab and nivolumab for metastatic kidney cancer patients. The treatment led to a 37% improvement in survival compared to sunitinib and durable responses in 42% of patients.
Researchers found that combining anti-CTLA-4 and anti-PD-1 immunotherapies enhances response rates and generates more memory T cells, leading to better tumor control. This combination may help prevent relapse in patients with therapies targeting CTLA-4 and PD-1 checkpoints.
The POPLAR trial found that atezolizumab significantly improved overall survival compared to docetaxel in previously treated advanced non-small-cell lung cancer patients. Long-term overall survival benefits were observed across histology and PD-L1 expression levels.
Researchers found that simultaneous chemotherapy and immunotherapy is safe and patients with certain genetic mutations may respond particularly well. The combination approach was shown to boost immune cells in the blood, allaying previous concerns about chemotherapy's impact on immunotherapy.
A study published in Science Translational Medicine reveals that macrophages suppress the activity of CD8 T cells, a type of immune cell that recognizes and kills melanoma cells. By disrupting macrophages, researchers found improved efficacy for immunotherapy in experimental models of melanoma.
A new pre-clinical study suggests that combining PD-1/PD-L1 antibodies with CD27 antibodies may lead to improved immune responses against cancer cells. The combination treatment showed up to 60% protection from cancer, compared to 10% with single treatments.
Researchers developed a new method to identify highly reactive killer T cells in ovarian tumors, showing they can be selectively grown for personalized cell-based immunotherapies. The approach overcomes limitations of existing methods, enabling the use of tumor-infiltrating lymphocytes for treating low-mutational load tumors.
A researcher uses mass cytometry technology to visualize a person's immune system, creating an 'Instagram' of millions of blood cells. This technique predicts cancer treatment responses and identifies potential biomarkers for patients who will respond positively to immunotherapy.
Jean-Charles Soria, a leading cancer researcher, has been awarded the TAT 2018 Honorary Award for his groundbreaking contributions to cancer drug development. His work has led to increased response rates and successful drug approvals, including osimertinib for lung cancer.
Researchers have made significant progress in treating non-small cell lung cancer (NSCLC) with the development of molecularly targeted therapies and immunotherapies. These treatments aim to attack tumor cells with mutated genes, but resistance is a common challenge.
Researchers identified biomarkers in blood samples that predict response to immunotherapy, allowing for personalized treatment decisions. High-dimensional cell analysis and computer-aided pattern recognition enabled the detection of subtle immune responses and molecular patterns associated with therapy success.
Researchers at Penn State found that melanoma patients who received immunotherapy with beta blockers lived significantly longer than those without, with five years survival rates of 70% vs. 25%. The study suggests reducing physiological stress with beta blockers can improve the effectiveness of immunotherapy.
Researchers at Dana-Farber Cancer Institute have identified a genetic mechanism that influences whether cancer cells resist or respond to immunotherapy drugs. The discovery reveals potential new drug targets and may aid efforts to extend the benefits of immunotherapy treatment to more patients.
A study by University of Chicago researchers found that specific strains of commensal bacteria can improve response rates to immunotherapy for patients with advanced melanoma. The presence of these beneficial bacteria enhances T-cell infiltration and killing of cancer cells, leading to a vigorous and durable response.
Researchers explore the use of nanoparticles, microneedle patches, and polymer particles to enhance vaccine effectiveness and delivery. These innovative biomaterials may improve responses in HIV, cancer, and autoimmune disorders, reducing medical waste and expanding vaccine accessibility.
Research at Columbia University Irving Medical Center found that cancer patients with more versions of human leukocyte antigen (HLA) genes respond better to checkpoint inhibitors. The study also showed that certain HLA patterns affect survival and may be relevant for understanding side effects observed with immunotherapy.
A new clinical trial found that combining oral immunotherapy with omalizumab increased the speed and safety of treating multiple food allergies in children. The study showed significant efficacy and safety improvements, allowing patients to tolerate more foods without severe reactions.
A new clinical trial shows that combining omalizumab with oral immunotherapy increases the ability of children with multiple food allergies to safely consume allergenic foods. The treatment resulted in over 80% of children being able to eat at least two grams of two or more foods without adverse reactions.
Researchers found non-progression during treatment correlates with gains in health-related quality of life in metastatic Merkel cell carcinoma patients. The study demonstrated that reduction in tumor size improves patients' health status, as measured by HRQoL instruments.
The combination of chemotherapy and immunotherapy significantly improves progression-free survival in patients with advanced non-squamous NSCLC. The study showed that the addition of atezolizumab to bevacizumab and chemotherapy leads to a median PFS of 8.3 months, compared to 6.8 months with bevacizumab and chemotherapy alone.
Researchers found that patients with more mutations in their tumors had better survival rates after adoptive T cell therapy. The treatment, which sharpens T cells to fight cancer, showed promising results but also many side effects.
New research from the University of Queensland shows that chronic stress can lead to a weakened immune response in cancer patients. The study found that lymphoma progression was accelerated in mouse models when stress pathways were induced, resulting in reduced effectiveness of immunotherapies.
Scientists at Mount Sinai developed a mathematical model that accurately predicts how tumors will respond to immunotherapies. The model also identifies key neoantigens that can stimulate an immune response, offering new insights for developing personalized cancer treatments.
Ludwig scientists present updates on checkpoint blockade immunotherapies for advanced melanoma and phase 1 clinical trials combining PI3K-gamma inhibitors with PD-1 blockade. Researchers also discuss novel approaches to boosting radiotherapy efficacy and understanding tumor immune suppression mechanisms.
Two studies reveal that gut bacteria play a crucial role in cancer treatment response, with certain beneficial microbes linked to improved survival and efficacy of immunotherapy. Patients with healthier gut flora tend to have more immune cells that can target tumors.
Prof Laurence Zitvogel has been awarded the first ESMO Award for Immuno-Oncology for her pioneering work in advancing cancer immunology and immunotherapy. Her research focuses on understanding the gut microbiome's role in cancer immunosurveillance, with implications for predicting response to immunomodulators.
Researchers found a strong association between certain beneficial gut bacteria and improved response to immunotherapies in patients with metastatic melanoma. The beneficial bacteria, including three specific species, were found to prime the immune system to attack cancer cells more effectively.
A study by University of California San Diego School of Medicine researchers reveals that a simple blood test can predict which patients will respond to checkpoint inhibitor-based immunotherapies, with 45% of patients showing significant response. The findings suggest that patients with high numbers of genomic alterations in their tumo...
Researchers at UC San Diego School of Medicine have developed a drug combination that doubles down on immunotherapy's effectiveness in treating head and neck cancer. The combination of toll-like receptors agonists and other immunotherapies injected directly into tumors suppresses tumor growth throughout the body.
Lymphatic vessels play a crucial role in both cancer metastasis and immune therapy. Researchers have discovered that VEGF-C levels in the blood before immunotherapy can predict its effectiveness in melanoma patients, with patients showing strong responses to treatment when VEGF-C levels are high.
A genetic study suggests that existing immunotherapy drugs could help some breast cancer patients with specific genetic changes in their tumors. The research identified a particular group of breast cancer patients who have genetic mutations that occur due to an abnormal DNA repair mechanism.
A study found that vessel growth created by tumors can enhance immunotherapy effects against melanoma. The growth secreted chemokines that attracted T cells into the tumor environment, leading to long-lasting anti-tumor immunity.
Researchers discovered that promoting T cells to use fat as energy instead of glucose increases their antitumor activity and improves T cell function within tumors. This metabolic shift also enhances the efficacy of immune checkpoint blockade therapy.
A special focus issue on immunotherapy has been published in Future Medicinal Chemistry, discussing the discovery and development of novel immunotherapeutic agents for use as anti-inflammatories and cancer treatments. The issue addresses recent scientific advances and challenges in this rapidly evolving field.
A recent study demonstrates the safety of immunotherapy in treating type 1 diabetes. The treatment showed metabolic effects without accelerating β-cell destruction, suggesting a viable option for patients.
A new NCI study identifies more than 100 genes necessary for cancer cells to respond to T cell-mediated killing, shedding light on resistance to immunotherapies. The findings offer a blueprint for studying tumor resistance and developing new therapeutics.
A new study found that patients with lower immune cell numbers, particularly those with exhausted T cells, benefit most from combination immunotherapy. Researchers developed an assay to measure immune cell populations and predict patient responses.
Researchers used Bio-Rad's Droplet Digital PCR to detect patient response to immunotherapies, identifying pseudoprogression. A biomarker detected by ddPCR indicates how well patients with non-small cell lung cancer respond to treatment, guiding toxic treatments only when necessary.
A new combination immunotherapy has significantly improved response rates for kidney cancer patients, with 40% experiencing prolonged responses. This treatment approach has the potential to set a new standard of care for kidney cancer patients, offering durable and reversible side effects compared to current therapies.
A phase III clinical trial shows that nivolumab improves response rates in stage IV lung cancer patients with specific molecular characteristics. The study found a 75% response rate among patients with high tumor mutation burden and PDL-1 positive status.
Scientists have discovered a new type of immune cell that can predict which lung cancer patients will benefit from immunotherapy treatment. The study found that patients with high levels of tissue-resident memory T-cells in their tumour were more likely to survive, and the cells' behaviour played a key role in increasing survival rates.
Researchers at La Jolla Institute for Allergy and Immunology identify tissue-resident memory T cells as an important distinguishing factor between cancer patients whose immune system mounts an effective anti-tumor response. The study found that patients with a high density of these cells in tumor tissue survived significantly longer.
Targeting a subset of immune cells called regulatory T cells could be an effective approach to treating cancers. By blocking or deleting a surface protein called neuropilin-1, researchers found that tumor growth was dramatically reduced in mice, suggesting this could lead to more effective immunotherapy treatments.
Researchers have identified histologic subtype distinctions and heterogeneity of neurofibromatosis type 1-associated tumors through immune profiling. The findings suggest potential targets for T cell-based immunotherapies, but also highlight the complexity of tumor heterogeneity within subtypes.
Researchers at Walter and Eliza Hall Institute have found a new way to use immunotherapy to treat triple negative breast cancers arising in women with BRCA1 mutations. The combination of two immunotherapy drugs effectively controls tumour growth and improves survival rates in laboratory models.
A new combination immunotherapy has shown promise in treating advanced kidney cancer, with the potential to identify biomarkers for many cancers. The study's principal investigator, Dr. Timothy Kuzel, hopes that this treatment will help more patients benefit from immunotherapy.
Researchers developed a novel mathematical model to explore interactions between prostate tumors and common immunotherapies, predicting their effects on patient-specific immune systems. The study highlights a potential therapeutic strategy for managing tumor growth more effectively.
Researchers found that commercial preparations for allergy shots often lack sufficient levels of key allergens, which could affect treatment success. Customized immunotherapy tailored to individual patients' reactions is a promising approach, but its development is still in its infancy.
Researchers at the University of Rochester Medical Center have developed a practical way to use light to guide T cells towards tumors, overcoming the challenges of immunotherapy. The innovative method could lead to safer and more effective treatment options for cancer patients.
Researchers found that certain lung cancer patients can continue treatment with immunotherapy even if the disease appears to be progressing, according to a study presented at ELCC 2017. The study used immune-related RECIST criteria, which take into account temporary tumour enlargement in patients taking immunotherapy.
A new study maps immune system components in early lung cancer, identifying potential targets for immunotherapy and suggesting a possible cure. The research reveals that early lesions are heavily infiltrated with immune cells, making immunotherapy a promising treatment option.